Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2020

The current state of antifungal stewardship among pediatric
antimicrobial stewardship programs
Lourdes Eguiguren
Stanford University

Jason G Newland
Washington University School of Medicine in St. Louis

Matthew P Kronman
University of Washington - Seattle Campus

Adam L Hersh
University of Utah

Jeffrey S Gerber
The Children's Hospital of Philadelphia

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Eguiguren, Lourdes; Newland, Jason G; Kronman, Matthew P; Hersh, Adam L; Gerber, Jeffrey S; Lee, Grace
M; and Schwenk, Hayden T, ,"The current state of antifungal stewardship among pediatric antimicrobial
stewardship programs." Infection Control & Hospital Epidemiology. ,. . (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9445

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Lourdes Eguiguren, Jason G Newland, Matthew P Kronman, Adam L Hersh, Jeffrey S Gerber, Grace M Lee,
and Hayden T Schwenk

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/9445

Infection Control & Hospital Epidemiology (2020), 1–6
doi:10.1017/ice.2020.306

Original Article
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Abstract
Objective: To characterize the current state of antifungal stewardship practices and perceptions of antifungal use among pediatric antimicrobial stewardship programs (ASPs).
Design: We developed and distributed an electronic survey, which included 17 closed-ended questions about institutional antifungal stewardship practices and perceptions, among pediatric ASPs.
Participants: ASP physicians and pharmacists of 74 hospitals participating in the multicenter Sharing Antimicrobial Reports for Pediatric
Stewardship (SHARPS) Collaborative.
Results: We sent surveys to 74 hospitals and received 68 unique responses, for a response rate of 92%. Overall, 63 of 68 the respondent ASPs
(93%) reported that they conduct 1 or more antifungal stewardship activities. Of these 68 hospital ASPs, 43 (63%) perform prospective audit
and feedback (PAF) of antifungals. The most common reasons reported for not performing PAF of antifungals were not enough time or
resources (19 of 25, 76%) and minimal institutional antifungal use (6 of 25, 24%). Also, 52 hospitals (76%) require preauthorization for
1 or more antifungal agents. The most commonly restricted antifungals were isavuconazole (42 of 52 hospitals, 80%) and posaconazole
(39 of 52 hospitals, 75%). Furthermore, 33 ASPs (48%) agreed or strongly agreed that antifungals are inappropriately used at their institution,
and only 25 of 68 (37%) of ASPs felt very confident making recommendations about antifungals.
Conclusions: Most pediatric ASPs steward antifungals, but the strategies employed are highly variable across surveyed institutions. Although
nearly half of respondents identified inappropriate antifungal use as a problem at their institution, most ASPs do not feel confident making
recommendations about antifungals. Future studies are needed to determine the rate of inappropriate antifungal use and the best antifungal
stewardship strategies.
(Received 15 April 2020; accepted 11 June 2020)

The prevention and management of invasive fungal infections is
challenging due to the difficulty in establishing a definitive diagnosis, limited therapeutic options, potential for treatment-related
adverse events, and high rates of morbidity and mortality.1,2 In
children, antifungal use has dramatically increased and shifted
to broader-spectrum agents.3,4 This increase is likely related to
higher numbers of immunocompromised patients at risk of invasive fungal infections and the use of prophylactic and empiric
antifungal therapy in this population.5,6 Also, significant variability
exists in antifungal use across adult and pediatric hospitals, suggesting possible misuse or overuse.7,8 The inappropriate use of
antifungals can lead to treatment failure, toxicities, increased costs,
and the emergence of resistance.9–11 Antimicrobial stewardship is a

widely established approach for monitoring and optimizing the use
of antimicrobials; however, most stewardship efforts have focused
on antibiotics and not antifungals.12,13 Antifungals have many
unique features: use in special populations (eg, immunocompromised patients, premature neonates), use for infections that are
often difficult to microbiologically confirm, variable correlation
between in vitro and in vivo activity, high cost, and requirement
for therapeutic drug monitoring (TDM). Thus, the stewardship
strategies employed for these agents may differ from those for antibiotics. We aimed to characterize the current state of antifungal
stewardship among pediatric ASPs and the perception of ASPs
regarding inappropriate antifungal use, antifungal stewardship,
and antifungal resistance.
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Methods
An electronic survey was developed based on published antimicrobial stewardship guidelines and specific antifungal stewardship
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interventions.14–17 An independent survey expert reviewed the
readability and design of the questionnaire; subsequently, the survey was pilot tested among a group of antimicrobial stewardship
physicians for relevance and content validity. The survey included
17 closed-ended questions exploring institutional antifungal stewardship practices and perceptions (Supplementary Fig. 1 online).
The survey included questions about prospective audit and feedback (PAF) and preauthorization, since these are the core elements
of antimicrobial stewardship described in the 2016 Infectious
Diseases Society of America (IDSA) and the Society for Healthcare
Epidemiology of America (SHEA) guidelines.14 We also asked
about other antifungal stewardship elements and interventions
reported in the literature, including mandatory infectious diseases
consultations for fungemia, antifungal TDM, publication of institutional antifungal susceptibility reports, and the use of fungal
markers.15–17 Lastly, we included questions related to perceptions
around inappropriate antifungal use, antifungal stewardship,
and antifungal resistance. We used Likert-type scales, binary
options, and multiple choice answers, as appropriate, to capture
the perceptions around antifungal stewardship (Supplementary
Fig. 1 online).
The survey was distributed electronically among pediatric
ASPs of 74 hospitals participating in the multicenter Sharing
Antimicrobial Reports for Pediatric Stewardship (SHARPS)
Collaborative. A member of the antimicrobial stewardship team
(physician or pharmacist) completed the survey at each institution.
Data were collected from December 2018 through February 2019.
Reminders were sent to nonrespondents at 2–3-week intervals during the data collection period. The first complete survey received
was included in the study and duplicate or incomplete surveys
from the same institution were excluded. Hospitals were deidentified prior to analysis.
We used descriptive statistics, including frequencies and proportions, to summarize the survey responses. We compared antifungal stewardship strategies and perceptions based on hospital
type, hospital beds, and geographic region using the χ2 test. The
statistical analysis was performed with JMP version 14.1 software
(SAS Institute, Cary, NC). Informed consent was obtained from
study participants. The study was approved by the Stanford
University School of Medicine Institutional Review Board.
Results
We received 68 unique responses from 74 hospitals, for a response
rate of 92%. We received surveys from 34 states and 2 international
sites. The respondents included 37 pediatric infectious diseases
physicians (54%) and 31 pharmacists (46%). Hospital characteristics of the participating pediatric ASPs are summarized in Table 1.
Overall, 93% of ASPs (63 of 68) reported that they conduct 1 or
more antifungal stewardship activities. Of the 68 respondent ASPs,
32 (47%) use both core stewardship strategies: PAF and preauthorization of antifungals. Also, 20 ASPs (30%) require preauthorization of antifungals alone, 11 (16%) perform PAF of antifungals
alone, and 5 (7%) do not perform any antifungal stewardship
activities.
Among pediatric ASPs, 43 of the 68 respondents (63%) perform
PAF of antifungals and 52 (76%) require preauthorization of 1 or
more antifungal agents. The characteristics of antifungal PAF and
preauthorization are shown in Table 2. No differences in antifungal
stewardship strategies were identified based on hospital type or
hospital beds. For those who do not audit antifungals, the most
common reasons for not performing PAF are insufficient time
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Table 1. Hospital Characteristics of Surveyed Pediatric Antimicrobial
Stewardship Programs
Characteristics

ASP Programs
(N = 68), No. (%)

Type of hospital
Freestanding children’s hospital

35 (52)

Children’s hospital within a hospital

32 (47)

Specialist children’s hospital

1 (1)

Geographic region
Northeast

10 (15)

Midwest

19 (28)

West

12 (17)

South

25 (37)

International

2 (3)

Hospital beds
<150

16 (24)

150–350

37 (54)

>350

15 (22)

Note. ASP, antimicrobial stewardship.

or resources (19 of 25, 76%) and minimal institutional antifungal
use (6 of 25, 24%).
At 58 of the 68 respondent hospitals (85%), TDM of antifungals
is routinely performed, and 23 of these 58 programs (40%) have a
pharmacokinetics program to assist with this effort. Of the 58 hospitals that reported antifungal TDM, all 58 (100%) perform TDM
for voriconazole and 46 (79%) perform TDM for posaconazole.
The target trough level reported for the treatment of suspected
invasive fungal infections varied across institutions (Fig. 1).
Among the responding hospitals, 10 (15%) reported that their hospital has a policy mandating pediatric infectious diseases consultation for patients with fungemia. Among hospitals without a
mandatory consult policy, most reported that pediatric infectious
diseases consultations occur with >75% of the cases of fungemia
(67%, 39 of 58). Also, 53 of 68 institutions (79%) reported using
noninvasive fungal markers when evaluating for invasive fungal
infections. The most commonly used fungal markers among these
institutions were serum aspergillus galactomannan (53 of 53,
100%) and (1,3)-β-D-glucan (41 of 53, 77%). Only 14 hospitals
(20%) reported that they include antifungal susceptibilities as part
of their institutional antibiogram.
A summary of the ASPs perceptions about antifungal use and
resistance is shown in Figure 2, with additional details in
Supplementary Table 1 (online). Compared to children’s hospitals
within a hospital, ASPs from freestanding children’s hospitals are
more likely to agree or strongly agree that antifungals are inappropriately used at their institutions (60% vs 34%, P = .03).
Likewise, respondents from large-size hospitals (>300 beds) are
more likely to agree or strongly agree that antifungals are inappropriately used at their institution than medium- and small-sized
hospitals (67% vs 51% vs 25%, P = .02). The perception of inappropriate use did not differ based on the respondent’s role. ASPs in
hospitals that reported antifungal susceptibilities were more likely
to perceive antifungal resistance as problem at their institutions
(64% vs 35%, P = .04). Only 25 ASPs (37%) reported feeling very
confident in providing antifungal recommendations. Respondents
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Table 2. Characteristics of Antifungal Stewardship Strategies Among Pediatric
Antimicrobial Stewardship Programs
Antifungal Stewardship Strategies
Antifungal prospective audit and feedback

ASP Programs
(N = 68), No. (%)
43 (63)

Antifungal monitored
Posaconazole

43 (100)

Echinocandins

42 (98)

Voriconazole

41 (95)

Amphotericin B (liposomal)

38 (88)

Isavuconazole

37 (86)

Amphotericin B (deoxycholate)

37 (86)

Fluconazole

32 (74)

Parameters monitored
Indication

43 (100)

Route

39 (91)

Pathogen–drug mismatch

39 (91)

Dose

38 (88)

Therapeutic drug monitoring

32 (74)

Most common recommendations
Stop antifungal

23 (53)

Convert intravenous to oral

21 (49)

Infectious diseases consult

21 (49)

Clarify indication

18 (42)

Therapeutic drug monitoring

17 (40)

Change dose

13 (30)

Switch drug

11 (25)

Frequency of monitoring
Daily

3 (7)

Monday–Friday

32 (74)

3 d per week

5 (12)

Once weekly
Antifungal preauthorization

3 (7)
52 (76)

Antifungal restricted
Isavuconazole

42 (80)

Posaconazole

39 (75)

Anidulafungin

32 (61)

Voriconazole

25 (48)

Micafungin

25 (48)

Caspofungin

23 (44)

Amphotericin B (liposomal)

21 (40)

Amphotericin B (deoxycholate)

13 (25)

Fluconazole

3 (6)

Note. ASP, antimicrobial stewardship.

reported that having clinical guidelines specific for antifungal use
in children and better diagnostics would improve their level of confidence in making antifungal recommendations (46%, 31 of 68 and
37%, 25 of 68, respectively). Furthermore, respondents perceived

hematology-oncology (32 of 68, 47%) and stem cell transplant
(15 of 68, 22%) as the services most likely to benefit from antifungal
stewardship interventions.
Discussion
Our survey revealed some of the antifungal stewardship practices
and perceptions in a cohort of pediatric ASPs. Most pediatric ASPs
have implemented some form of antifungal stewardship, and the
strategies employed are highly variable across surveyed hospitals.
Interestingly, although nearly half of respondents perceived inappropriate antifungal use as a problem at their hospital, many did
not feel confident in providing antifungal recommendations.
Specific stewardship strategies, including antifungal TDM and
fungal susceptibility reporting, appear to be less common and
may represent unique and important antifungal stewardship
opportunities.
According to our survey results, the core antimicrobial stewardship strategies, PAF and preauthorization, have been expanded to
include antifungals in most pediatric ASPs. Although these antifungal stewardship interventions have been shown to successfully
reduce antifungal consumption in hospitalized patients, the best
approach to antifungal stewardship remains unknown.5,17–20
This lack of comparative data has likely led to the very heterogenous and hospital-specific approaches illustrated in this study.
Some studies have proposed that PAF and more intensive stewardship strategies like daily PAF in combination with preauthorization
and formulary restriction, may be more effective in decreasing
antibiotic utilization.21,22 Whether the same is true for antifungals
is unknown. In our study, the use of preauthorization was more
common than PAF, which is considered relatively labor
intensive.14 Similar to prior reports evaluating antibiotic stewardship strategies, respondents reported that the biggest barrier
to implementing antifungal PAF was a lack of time and
resources.23–25 The frequency of antifungal monitoring varied
widely, with <10% of programs performing daily PAF. Whether
the absence of daily PAF reflects a lack of sufficient resourcing
or is a purposeful choice is uncertain; however, it may result in
missed opportunities to intervene and improve antifungal prescribing. These findings highlight the importance of identifying
effective antifungal stewardship interventions to better utilize
and optimize current resources.
The characteristics of antifungal PAF and preauthorization varied across hospitals. For example, the survey detected differences in
the types of antifungals monitored as part of PAF and restricted as
part of preauthorization programs. Broad-spectrum triazoles,
including voriconazole, posaconazole, and isavuconazole, were
commonly targeted as part of antifungal stewardship efforts.
ASPs may focus their efforts on these antifungals given the need
for TDM, potential toxicities, and their higher costs.26,27 However,
fluconazole may represent an important antifungal stewardship
target because it accounts for ~70% of antifungal prescriptions in
children4 and has been associated with inappropriate prescribing
in neonates and children.1,28
The TDM of azole medications is an important strategy to
ensure the appropriate use of antifungals and mitigate adverse
events.29 Most institutions responding to this survey routinely
monitor azole levels; however, TDM was the least commonly
monitored parameter among ASPs performing PAF of antifungals,
and only a few institutions reported having a pharmacokinetics
program to assist with antifungal TDM. These findings suggest
that most clinicians conduct TDM of antifungals without expert
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Fig. 1. Voriconazole and posaconazole target therapeutic levels reported by pediatric antimicrobial stewardship programs.
Note. TDM, therapeutic drug monitoring.

Fig. 2. Perceptions about antifungal use and stewardship among pediatric antimicrobial stewardship programs.

guidance from pharmacists or ASP team members, which may
increase the risk for medication errors and suboptimal dosing.
Antifungals can be particularly challenging to use in children given
their unique pharmacokinetic and pharmacodynamic characteristics. For example, studies have shown that up to 50% of antifungals
are inadequately dosed and that certain antifungals require multiple dose adjustments to achieve therapeutic levels.5,28,30,31 Our
study revealed variability in the target therapeutic levels reported
across institutions, which suggests a lack of consensus in current
practices and an important opportunity for standardization.
Many of the survey respondents reported a lack of confidence in
making antifungal recommendations. This important finding

could be related to the limited diagnostic information available
to guide antifungal stewardship recommendations. Indeed, almost
40% of the respondents in our survey reported that having better
diagnostics would improve their level of confidence in making
antifungal recommendations. The absence of microbiological data
may limit the ability of ASPs to identify opportunities for discontinuation or de-escalation of antifungals and contribute to prolonged courses of prophylactic or empiric antifungals. Previous
surveys have shown that de-escalation of broad-spectrum antibiotic therapy on the basis of culture results is one of the most
common antibiotic stewardship interventions.23 In contrast, our
study found that the recommendation to switch antifungals (ie,
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de-escalate therapy) was one of the least commonly reported interventions. As a surrogate for culture data, the use of noninvasive
fungal markers was common among the surveyed hospitals.
Prior studies have evaluated the use of noninvasive fungal markers
for the surveillance of invasive fungal infection in stem cell
transplant patients in an effort to shift from a prophylactic to a preemptive approach and decrease potentially unnecessary antifungal
exposure.32–34 Further studies exploring the safety and utility of
these tests as part of antifungal stewardship interventions in the
pediatric population are warranted.
Inappropriate and unnecessary antifungal use was considered a
problem by most pediatric ASPs in this study. Oncology and stem
cell transplant were reported as the services that would benefit the
most from antifungal stewardship, likely because of the disproportionally higher antifungal utilization described in this population.7
Also, most ASPs in this cohort identified antifungal resistance
as a national problem, and to a lesser extent, an institutional problem. This perception may be due to the recent emergence of
multidrug-resistant Candida auris outbreaks in hospitals across
the United States.35 Most of these cases have been reported in
adults; therefore, respondents of this study may consider issues
of antifungal resistance as a national, rather than local, problem.
Only 20% of the hospitals reported antifungal susceptibilities as
part of the institutional antibiogram, and ASPs in these hospitals
were more likely to perceive antifungal resistance as a problem at
their institution. Possibly, therefore, resistant fungal organisms are
underreported or ASP team members are not aware of institutional
antifungal susceptibility trends. The emergence of antifungal resistance has been increasingly recognized, and understanding the
local epidemiology is essential to developing institutional guidelines for antifungal prophylaxis and the empiric treatment of
fungal infections.
Our study has several limitations. First, these results may not be
generalizable to all pediatric hospitals. Although our response rate
was high, we only surveyed ASPs participating in the SHARPS
Collaborative, in which members are actively involved in identifying
best practices for the use of antimicrobials. Therefore, we may be
overestimating the extent to which antifungal stewardship practices
are occurring. However, we were able to capture responses from
both freestanding children’s hospitals and children’s hospitals
within a larger adult hospital. In addition, ASPs from all 4
geographic regions in the United States and 2 international sites
in Europe were represented in our cohort. Another limitation is that
some of the responses may have been influenced by the respondent’s
familiarity with their institution’s resources and practices and may
represent perception rather than fact. Finally, we did not evaluate the
effectiveness of different antifungal stewardship interventions,
which should be further explored in future studies.
Although implementing antifungal stewardship has challenges,
it has the potential to decrease unnecessary and suboptimal antifungal use, to reduce toxicities associated with inappropriate antifungal use, and to prevent the emergence of antifungal resistance.
Currently, PAF and preauthorization are the main strategies used
by pediatric ASPs to perform antifungal stewardship. Future studies should evaluate the effectiveness and clinical impact of such
interventions. Optimization of antifungal dosing and TDM via
ASPs represent key components of antifungal stewardship in pediatrics. Thus, future antifungal stewardship efforts should focus not
only on reducing unnecessary use but also on improving the quality of antifungal prescribing.
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